| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
2H-Indazole, 2-[(2-chloro-4-fluorophenyl)Methyl]-3-(4-fluorophenyl)-7-(trifluoroMethyl)-
|
875787-07-8 |
2-[(2-氯-4-氟苯基)甲基]-3-(4-氟苯基)-7-(三氟甲基)-2H-吲唑
|
2-(2-氯-4-氟苄基)-3-(4-氟苯基)-7-(三氟甲基)-2H-吲唑;2-[(2-氯-4-氟苯基)甲基]-3-(4-氟苯基)-7-(三氟甲基)-2H-吲唑;CS-758;WAY-252623;LXR623;LXR 623;WAY252623;WAY 252623;LXR623;LXR-623
|
C21H12N2F5Cl |
422.77838 | |
|
CPPHA
|
693288-97-0 |
N-[4-氯-2-[(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)甲基]苯基]-2-羟基苯甲酰胺
|
N-[4-氯-2-[(1,3-二氢-1,3-二氧代-2H-异吲哚-2-基)甲基]苯基]-2-羟基苯甲酰胺
|
C22H15ClN2O4 |
406.8185 | |
|
C7280948
|
587850-67-7 |
C7280948
|
C 7280948;C-7280948;C7280948>98%;4-氨基-N-(2-苯基乙基)苯磺酰胺
|
C14H16N2O2S |
276.36 | |
|
CAY10683 (SantacruzaMate A)
|
1477949-42-0 |
ETHYL 4-OXO-4-(PHENETHYLAMINO)BUTYLCARBAMATE
|
CS-1702;CAY 10683;CAY-10683;SANTACRUZAMATE A>98%;ETHYL 4-OXO-4-(PHENETHYLAMINO)BUTYLCARBAMATE;HDAC抑制剂
|
C15H22N2O3 |
278.34678 | -0 |
|
YK-4-279
|
1037184-44-3 |
YK 4-279
|
CS-1785;4,7-二氯-1,3-二氢-3-羟基-3-[2-(4-甲氧基苯基)-2-氧代乙基]-2H-吲哚-2-酮;YK-4-279;YK 4-279
|
C17H13NO4Cl2 |
366.19542 | |
|
UNC 669
|
1314241-44-5 |
UNC669
|
(5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮
|
C15H20BrN3O |
338.2428 | |
|
AM095
|
1228690-36-5 |
[4'-[3-甲基-4-[[[((R)-1-苯基乙基)氧基]羰基]氨基]异恶唑-5-基]联苯-4-基]乙酸
|
AM-095 (free base);AM095 (free acid);[4'-[3-Methyl-4-[[[((R)-1-phenylethyl)oxy]carbonyl]amino]isoxazol-5-yl]biphenyl-4-yl]acetic acid;AM 095 (parent compound);2-[4-[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetic Acid
|
C27H24N2O5 |
456.48986 | |
|
AZ-20
|
1233339-22-4 |
AZ20
|
AZ-20;AZ 20;CS-1335;4-[4-[(3R)-3-甲基-4-吗啉基]-6-[1-(甲基磺酰基)环丙基]-2-嘧啶基]-1H-吲哚
|
C21H24N4O3S |
412.50526 | |
|
IM-12
|
1129669-05-1 |
IM-12
|
THE GSK3Β INHIBITOR XIX;IM 12;IM-12;IM12;CS-2144;CS-1819;3-[[2-(4-氟苯基)乙基]氨基]-1-甲基-4-(2-甲基-1H-吲哚-3-基)-1H-吡咯-2,5-二酮
|
C22H20FN3O2 |
377.4115032 | |
|
(+)PD 128907
|
300576-59-4 |
(+)-PD 128907, 盐酸盐
|
(4AR,10AR)-1-丙基-2,3,10,10A-四氢-1H,4AH-4,9-二氧杂-1-氮杂菲-6-醇盐酸盐
|
C14H19NO3.HCl |
285.7665 | |
|
2-Acetylfuro-1,4-naphthoquinone
|
83280-65-3 |
2-乙酰基呋喃并-1,4-萘醌
|
BBI608(那布卡辛);2-乙酰基呋喃并-1,4-萘醌;那布卡辛;2-乙酰基呋喃并-1,4-萘醌 5G;那帕卡辛;2-乙酰基萘并[2,3-B]呋喃-4,9-二酮;BBI-606;CS-945
|
C14H8O4 |
240.21092 | |
|
PI-103 Hydrochloride
|
371935-79-4 |
PI-103, HYDROCHLORIDE SALT, >99%
|
3-[4-(4-吗啉基)吡啶并[3',2':4,5]呋喃并[3,2-D]嘧啶-2-基]苯酚单盐酸盐;PI 103 HYDROCHLORIDE;PI103 HYDROCHLORIDE
|
C19H17ClN4O3 |
384.81628 | |
|
LDN193189 Hydrochloride
|
1062368-62-0 |
LDN-193189 HCl
|
4-(6-(4-(哌嗪-1-基)苯基)吡唑并[1,5-A]嘧啶-3-基)喹啉盐酸盐;CS-1451;4-[6-[4-(1-哌嗪基)苯基]吡唑并[1,5-A]嘧啶-3-基]喹啉盐酸盐;4-(6-(4-(哌嗪-1-基)苯基)吡唑并[1,5-A]嘧;LDN193189 盐酸盐,一种选择性的 BMP I 型受体激酶抑制剂;LDN-193189 HCL;LDN 193189 HCL
|
C25H23ClN6 |
442.94332 | |
|
5-chloro-N-(4-methoxy-3-(piperazin-1-yl)phenyl)-3-methylbenzo[b]thiophene-2-sulfonamide hydrochloride
|
209481-20-9 |
5-氯-N-[4-甲氧基-3-(1-哌嗪基)苯基]-3-甲基苯并[B]噻吩-2-磺酰胺
|
5-氯-N-[4-甲氧基-3-(1-哌嗪基)苯基]-3-甲基苯并[B]噻吩-2-磺胺;SB271046 HCL;5-氯-N-[4-甲氧基-3-(1-哌嗪基)苯基]-3-甲基苯并[B]噻吩-2-磺酰胺
|
C20H23CL2N3O3S2 |
488.45092 | |
|
4-(1H-IMIDAZOL-4-YLMETHYL)PIPERIDINE DIHYDROBROMIDE
|
164391-47-3 |
4-(1H-咪唑基-4-甲基)哌啶二氢溴酸盐
|
4-(1H-咪唑基-4-甲基)哌啶二氢溴酸盐;4-(1H-咪唑-5-甲基)哌啶氢溴酸盐;IMMEPIP 氢溴酸盐;4-(1H-咪唑-4-甲基)-哌啶二溴酸盐
|
C9H15N3.2[HBr] |
327.05938 | |
|
3,4-dimethoxy-N-[4-(3-nitrophenyl)-1,3-thiazol-2-yl]benzenesulfonamide
|
199666-03-0 |
RO 61-8048
|
3,4-二甲氧基-N-[4-(3-硝基苯基)-2-噻唑基]苯磺酰胺;3,4-二甲氧基-N-[4-(3-硝基苯)-噻唑]苯磺酰胺;3,4-二甲氧基-N-[4-(3-硝基苯基)-2-噻唑基]苯磺酰胺;CS-1828
|
C17H15N3O6S2 |
421.4475 | |
|
Nexturastat A
|
1403783-31-2 |
4-((1-BUTYL-3-PHENYLUREIDO)METHYL)-N-HYDROXYBENZAMIDE
|
4-((1-BUTYL-3-PHENYLUREIDO)METHYL)-N-HYDROXYBENZAMIDE;4-[[丁基[(苯基氨基)羰基]氨基]甲基]-N-羟基苯甲酰胺;CS-1289;NEXTURASTAT A>97%
|
C19H23N3O3 |
341.40422 | |
|
FMK
|
821794-92-7 |
FMK
|
FMK;1-[4-氨基-7-(3-羟基丙基)-5-(4-甲基苯基)-7H-吡咯并[2,3-D]嘧啶-6-基]-2-氟乙酮
|
C18H19FN4O2 |
342.367463 | |
|
FPH2
|
957485-64-2 |
FPH2(BRD-9424)
|
4-[[[(5-氯-2-甲氧基苯基)氨基]硫代甲酰]氨基]-1-乙基-1H-吡唑-3-甲酰胺;FPH2(BRD-9424)
|
C14H16ClN5O2S |
353.82714 | |
|
Sotrastaurin (AEB071)
|
425637-18-9 |
3-(1H-吲哚-3-基)-4-[2-(4-甲基哌嗪-1-基)喹唑啉-4-基]吡咯-2,5-二酮
|
CS-1479;3-(1H-吲哚-3-基)-4-[2-(4-甲基哌嗪-1-基)喹唑啉-4-基]吡咯-2,5-二酮;AEB071;AEB 071;AEB-071;索曲妥林
|
C25H22N6O2 |
438.48118 |
药智官方微信
药智官方微博
